Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
Afatinib plus necitumumab was safe but had limited activity in patients with <i>EGFR-</i>mutated NSCLC. Biomarker studies may identify patient subgroups that are more likely to benefit.
Authors
- Wade T. Iams (ORCID: https://orcid.org/0000-0003-2109-298X)
- Lynne D. Berry (ORCID: https://orcid.org/0000-0001-7700-2918)
- Joel W. Neal (ORCID: https://orcid.org/0000-0003-3119-9334)
- Heather A. Wakelee (ORCID: https://orcid.org/0000-0003-1136-980X)
- Karen L. Reckamp (ORCID: https://orcid.org/0000-0002-9213-0325)
- Sukhmani K. Padda (ORCID: https://orcid.org/0000-0002-8691-7754)
- Yu Shyr (ORCID: https://orcid.org/0000-0003-2086-9670)
- Leora Horn (ORCID: https://orcid.org/0000-0003-2070-2547)
- Sally J. York (ORCID: https://orcid.org/0009-0005-2194-964X)
- Jennifer G. Whisenant (ORCID: https://orcid.org/0000-0002-3435-2464)
- Nathaniel J. Myall
Institutions
- Cedars-Sinai Medical Center (US)
- Fox Chase Cancer Center (US)
- Temple University Health System (US)
- Vanderbilt University Medical Center (US)
- Stanford University (US)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1016/j.jtocrr.2024.100757
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Boehringer Ingelheim
- National Comprehensive Cancer Network